1 tral endopeptidase 24.11 (NEP) are the major kininases, as determined first with specific substrates

2 , the plasma membrane AP-P can function as a kininase, but little is known about the physiological ro

3 AA release by BK was reduced by 40% by added kininase I (carboxypeptidase M); however, receptor activ

4 it as carboxypeptidase N (CPN, also known as kininase I, arginine carboxypeptidase, and anaphylotoxin

5                            Inhibitors of ACE/kininase II enhance insulin sensitivity, an action that

6 wever, angiotensin-converting enzyme is also kininase II, which serves to increase endogenous kinin a

7  heart and skeletal muscle membranes contain kininase II-type enzymes, but their activity depends on

8                                          The kininase II/angiotensin-converting enzyme inhibitor enal

9             Angiotensin I converting enzyme (kininase II; ACE) inhibitors are important therapeutic a

10 f action of angiotensin I-converting enzyme (kininase II; ACE) inhibitors mediated through the direct

11 oassay (bradykinin 10 nmol/l), 46 and 55% of kininase in rat and dog skeletal muscle P3, respectively

12  neutral endopeptidase 24.11 is an important kininase in skeletal muscle, we examined the effect of t

13 e uptake by skeletal muscle, we investigated kininases in these tissues.